Fluorodopa f-18 - PharmaKB

Fluorodopa f 18

Fluorodopa F (fluorodopa f 18) is a small molecule pharmaceutical. Fluorodopa f 18 was first approved as Fluorodopa f18 on 2019-10-10.

Download report

Favorite

FDA Novel Drug Approvals 2019

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

No data

Trade Name

FDA

EMA

No data

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

No data

Labels

FDA

EMA

Brand Name	Status	Last Update
fluorodopa	New Drug Application	2021-01-15

Indications

FDA

EMA

No data

Agency Specific

FDA

EMA

Expiration	Code
FLUORODOPA F-18, FLUORODOPA F18, FEINSTEIN
2024-10-10	NCE, W

Patent Expiration

No data

ATC Codes

V: Various drug classes in atc

— V09: Diagnostic radiopharmaceuticals

— V09I: Tumour detection radiopharmaceuticals

— V09IX: Other diagnostic radiopharmaceuticals for tumour detection in atc

— V09IX05: Fluorodopa (18f)

HCPCS

No data

Clinical

Clinical Trials

2412 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Prostatic neoplasms	D011471	—	C61	49	74	37	10	99	250
Alzheimer disease	D000544	EFO_0000249	F03	70	54	24	8	76	222
Neoplasms	D009369	—	C80	77	41	4	3	92	205
Breast neoplasms	D001943	EFO_0003869	C50	47	46	6	5	81	179
Non-small-cell lung carcinoma	D002289	—	—	20	26	6	1	42	89
Lung neoplasms	D008175	—	C34.90	19	16	8	2	42	81
Brain neoplasms	D001932	EFO_0003833	C71	24	20	4	2	35	81
Parkinson disease	D010300	EFO_0002508	G20	24	22	6	1	32	80
Neoplasm metastasis	D009362	EFO_0009708	—	10	10	2	1	24	47
Disease	D004194	EFO_0000408	R69	5	9	7	2	24	43

Show 57 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	65	11	2	—	17	94
Cognitive dysfunction	D060825	—	G31.84	11	24	7	—	35	75
Glioma	D005910	EFO_0000520	—	18	9	3	—	31	60
Head and neck neoplasms	D006258	—	—	17	14	1	—	31	60
Squamous cell carcinoma of head and neck	D000077195	—	—	20	15	2	—	14	47
Dementia	D003704	EFO_0003862	F03	8	12	4	—	27	47
Renal cell carcinoma	D002292	EFO_0000376	—	15	17	1	—	16	42
Hepatocellular carcinoma	D006528	—	C22.0	9	10	1	—	21	40
Pancreatic neoplasms	D010190	EFO_0003860	C25	15	6	1	—	20	39
Liver neoplasms	D008113	EFO_1001513	C22.0	6	9	2	—	22	37

Show 86 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Glioblastoma	D005909	EFO_0000515	—	18	16	—	—	22	53
Melanoma	D008545	—	—	9	11	—	—	16	36
Inflammation	D007249	MP_0001845	—	6	8	—	—	16	29
Non-hodgkin lymphoma	D008228	—	C85.9	5	7	—	—	12	24
Hypoxia	D000860	—	R09.02	1	6	—	—	15	22
Pick disease of the brain	D020774	EFO_0003096	G31.01	6	2	—	—	14	22
Large b-cell lymphoma diffuse	D016403	—	C83.3	4	5	—	—	10	19
Tauopathies	D024801	—	—	5	4	—	—	10	19
Rectal neoplasms	D012004	—	—	3	4	—	—	12	18
Frontotemporal dementia	D057180	—	G31.0	8	6	—	—	4	17

Show 154 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Progressive supranuclear palsy	D013494	EFO_0002512	G23.1	12	—	—	—	6	18
Hematologic neoplasms	D019337	—	—	2	—	—	—	8	10
Huntington disease	D006816	Orphanet_399	G10	4	—	—	—	4	8
Meningioma	D008579	EFO_0003098	D32.9	3	—	—	—	4	7
Central nervous system neoplasms	D016543	—	—	4	—	—	—	3	7
Pituitary neoplasms	D010911	—	—	2	—	—	—	4	6
Nervous system diseases	D009422	—	G00-G99	1	—	—	—	5	6
Rheumatoid arthritis	D001172	EFO_0000685	M06.9	4	—	—	—	2	6
Post-traumatic stress disorders	D013313	EFO_0001358	F43.1	1	—	—	—	5	6
T-cell lymphoma peripheral	D016411	—	—	2	—	—	—	4	6

Show 108 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Papillary thyroid cancer	D000077273	—	—	—	—	—	—	9	9
Thrombosis	D013927	—	—	—	—	—	—	8	8
Extranodal nk-t-cell lymphoma	D054391	—	C86.0	—	—	—	—	6	6
Acute coronary syndrome	D054058	EFO_0005672	—	—	—	—	—	5	5
Infections	D007239	EFO_0000544	—	—	—	—	—	4	4
Ischemic stroke	D000083242	—	—	—	—	—	—	4	4
Primary myelofibrosis	D055728	—	D47.4	—	—	—	—	4	4
Psychotic disorders	D011618	—	F20.81	—	—	—	—	3	3
Insulin resistance	D007333	EFO_0002614	E88.819	—	—	—	—	3	3
Metabolic syndrome	D024821	EFO_0000195	E88.810	—	—	—	—	3	3

Show 273 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Fluorodopa f 18
INN	fluorodopa (18f)
Description	6-((18)F)fluoro-L-dopa is a 6-fluoro-L-dopa and a (18)F radiopharmaceutical.
Classification	Small molecule
Drug class	dopamine receptor agonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	N[C@@H](Cc1cc(O)c(O)cc1[18F])C(=O)O